The FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease as it takes on rivals such as Johnson & Johnson.
PARP, or poly (ADP-ribose) polymerase, inhibitors may have an amusing-sounding name but an increasing body of evidence suggest they could be used in a wide range of cancers as long as certa
Johnson & Johnson is hoping to expand the use of its prostate cancer drug Erleada (apalutamide) in patients with metastatic castration-sensitive prostate cancer (mCSPC) – and new data p
High-profile digital health investor Luba Greenwood recently announced that she’s joined as Chair of the Board at Closed Loop Medicine, a company applying machine learning to precision drug